SCHEMBL5887467

SCHEMBL5887467

COc1ccc(CNC(=O)c2ccc(-n3c(=O)ccc4c(C)nc(N5CCN(C(=O)c6cc(OC)c(OC)c(OC)c6)CC5)nc43)cc2)cc1OC

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.46
LMNA P02545 5/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
HTT P42858 2/20 0.44
GAA P10253 2/20 0.44
NPC1 O15118 2/20 0.42
POLB P06746 1/20 0.42
GFER P55789 1/20 0.42
ALDH1A1 P00352 4/20 0.41
MAPT P10636 2/20 0.40
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
TP53 P04637 1/20 0.40
THRB P10828 1/20 0.40
MAPK1 P28482 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887689 0.93 ALDH1A1 (0.42) KDM4ELMNASMN1; SMN2HTTGAA
SCHEMBL5886855 0.93 ALDH1A1 (0.42) KDM4ELMNASMN1; SMN2HTTGAA
SCHEMBL5887135 0.92 ALDH1A1 (0.43) LMNASMN1; SMN2HTTNPC1POLB
SCHEMBL5887006 0.92 ACHE (0.48) LMNASMN1; SMN2HTTGAANPC1
SCHEMBL5887119 0.91 LMNA (0.41) KDM4ELMNASMN1; SMN2HTTGAA
SCHEMBL5886766 0.91 NPC1 (0.45) LMNASMN1; SMN2GAANPC1GFER
SCHEMBL5886825 0.91 NPC1 (0.45) KDM4ELMNASMN1; SMN2GAANPC1
SCHEMBL5887364 0.90 ALDH1A1 (0.40) KDM4ELMNASMN1; SMN2HTTGAA
SCHEMBL5887375 0.89 NPC1 (0.44) LMNASMN1; SMN2NPC1POLBGFER
SCHEMBL5887334 0.89 ALDH1A1 (0.44) KDM4ELMNASMN1; SMN2HTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP KDM4E 840/4885LMNA 711/4885SMN1; SMN2 2219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.